Arriving on the one-year anniversary of nationwide COVID-19 shutdowns, the 2021 Conference on Retroviruses and Opportunistic Infections won't be in person this year—but it will emphasize COVID-19 alongside important HIV prevention and treatment updates.
At the University of Nebraska Medical Center, HIV care providers scrambled to set up new systems in hopes of maintaining retention in care and viral suppression among as many patients as possible.
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
“The message that needs to be communicated to people in power, and it needs to be communicated loud and frequently, is, ‘Look. Here’s the actual human cost of not enacting these kinds of policies. Here’s the potential benefit,’” says Aaron Richterman, M.D., M.P.H.
A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.
IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
HIV and TB often go hand in hand among people experiencing homelessness in the U.S.—a reality that gives public health officials an opportunity to utilize shelters in tackling both viruses at the same time.
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.